Amgen Inc.
Amgen Inc. Discloses Material Cybersecurity Incident
Summary
In July 2026, Amgen Inc. identified unauthorized activity involving data stored in cloud environments hosted by third-party cloud service providers. The company has determined that some of its data, including proprietary data, patient protected health information, and other information, has been exfiltrated. Amgen has activated its cybersecurity response plan, implemented containment measures, and engaged independent cybersecurity forensic experts. The company continues to assess the potential impact of the incident and will make all required notifications based on its findings. As of the date of this filing, Amgen believes the incident is not reasonably likely to have a material impact on its financial condition or results of operations.
Profitelligence Alerts
Get alerts for AMGN
Be first to know when Amgen Inc. files with the SEC.
Filing Categories
Advertisement
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Official SEC Documents
Advertisement